SUNDAY 10 OCTOBER 2021
08:00
Sponsored Diagnostic Symposium 1
More information on www.timm2021.org/sponsored-symposia
Plenary session 3 Viral infection associated Pulmonary Aspergillosis / Going Viral Going Fungal
Chairs: Tihana Bicanic, United Kingdom, FECMM & Oliver Cornely, Germany, FECMM
09:00
PS3.1 Influenza
Paul Verweij, the Netherlands, FECMM
09:30
PS3.2 COVID-19
Martin Hoenigl, Austria, FECMM
10:00
Coffee break
10:15
Quiz the expert sessions
10:15
Q07 MIC testing in the lab
Maiken Arendrup, Denmark & Joseph Meletiadis, Greece
10:15
Q08 Mucormycosis how to manage
Livio Pagano, Italy, FECMM & Sharon Chen, Australia, FECMM
10:15
Q09 TDM
Andreas Groll, Germany, FECMM & Chin Fen Neoh, Malaysia, FECMM
10:15
Q10 Radiology
Joanne Cleverley, United Kingdom & Bruno Hochhegger, Brazil, FECMM
10:15
Q11 How to use new antifungals in kids
Fabianne Carlesse, Brazil & Emmanuel Roilides, Greece, FECMM
10:15
Q12 Mycological Diagnosis on the bedside: Where are we in 2021
John Perfect, USA & Toine Mercier, Belgium, FECMM
11:00
Poster session 2
12:00
Lunch
12:30
Sponsored Integrated Symposium 4
More information on www.timm2021.org/sponsored-symposia
14:15
Parallel Symposia 14-17
Symposium 14 Fungal respiratory infections in Cystic Fibrosis
Chairs: Jean-Philippe Bouchara, France & Michaela Lackner, Austria, FECMM
14:15
S14.1 Fungal respiratory infections in Cystic Fibrosis
Michaela Lackner, Austria, FECMM
14:35
S14.2 Exophiala dermatitidis in cystic fibrosis
Jörg Steinmann, Germany, FECMM
14:55
S14.3 Immunotherapy
Darius Armstrong-James, United Kingdom, FECMM
15:15
S14.4 Genotypic and phenotypic portrait of Candida albicans clinical isolates colonizing the airways of patients with cystic fibrosis
Mayssa Gnaien, Tunisia
15:30
S14.5 Exophiala dermatitidis infection in Cystic Fibrosis accelerates lung function decline; a retrospective single-centre review of historical lung function
Jonathan Ayling-smith, United Kingdom
Symposium 15 Cryptococosis: From bench to bedside
Chairs: Valentina Arsic Arsenijevic, Serbia, FECMM & Tom Harrison, United Kingdom
14:15
S15.1 Cryptococcus qPCR assays: the future for routine mycology labs and clinical trials dealing with cryptococcosis – An AMBITION sub-study
Alexandre Alanio, France, FECMM
14:35
S15.2 AMBITION trial and beyond
Joe Jarvis, United Kingdom
14:55
S15.3 Titan cells in cryptococcosis
Liz Ballou, United Kingdom
15:15
S15.4 Modifications of the cell wall in cryptococcosis
Liliane Mukaremera, United Kingdom
15:35
S15.5 Molecular analysis of Cryptococcus spp. reveals species diversity and Multilocus Sequence Typing heterogeneity among people living with HIV in Kinshasa
Bive Zono, Congo
Symposium 16 Azoles, Echinocandins and Polyenes strenghts and weaknesses
Chairs: Gordon Ramage, United Kingdom, FECMM & Marika Jürna-Ellam, Estonia
14:15
S16.1 Azoles
Roger Brüggemann, the Netherlands, FECMM
14:35
S16.2 Echinocandins
Andrej Spec, USA, FECMM
14:55
S16.3 Managing antifungal tolerant biofilms: our current understanding and future directions
Gordon Ramage, United Kingdom, FECMM
15:15
S16.4 Breakthrough infections - Definitions, Epidemiology and Outcomes
Jeff Jenks, USA
15:25
S16.5 Ibrexafungerp is effective in treating murine mucormycosis caused by Rhizopus delemar
Ashraf Ibrahim, United States
15:35
S16.6 Lanosterol 14-alpha-demethylase-F5 homologue mediates short-tailed azole resistance in mucormycetes: Characterization of Mucor circinelloides LDM-genes in the heterologous model S. cerevisiae
Katharina Rosam, Austria
Symposium 17 Management of immunoallergic fungal diseases
Chairs: Tom Rogers, Ireland & Jean-Pierre Gangneux, France, FECMM
14:15
S17.1 Antifungal treatment in kids with allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization : where do we stand?
Adilia Warris, United Kingdom, FECMM
14:35
S17.2 severe asthma and the role of aspergillis
Peter Cook, United Kingdom
14:55
S17.3 Impact of environmental approaches for allergen avoidance and asthma control
Jean-Pierre Gangneux, France, FECMM
15:15
S17.4 Type 2-high asthma patients reveal a specific indoor mycobiome and microbiome
Laurence Delhaes, French Guiana
15:30
S17.5 Antifungal therapeutic outcomes in Allergic Bronchopulmonary Aspergillosis (ABPA) patients with asthma
Lisa Nwankwo, United Kingdom
15:45
Coffee break
16:15
Parallel Symposia 18-21
Symposium 18 Diagnosis of invasive aspergillosis: What is new?
Chairs: Lewis White, UK, FECMM & Petr Hamal, Czech Republic, FECMM
16:15
S18.1 Multicenter evaluation of the VirClia galactomannan assay on bronchoalveolar lavage fluid from patients with hematological malignancies
Jochem Buil, the Netherlands
16:35
S18.2 Point-of-care testing
Juergen Prattes, Austria, FECMM
16:55
S18.3 PCR Diagnosis
Lewis White, United Kingdom, FECMM
17:15
S18.4 Urine Aspergillus Antigen Detection as an Aid to Diagnose Invasive Aspergillosis
Kieren Marr, USA
17:25
S18.5 Proteomic Analysis of Humoral Immune Components in Bronchoalveolar Lavage of Patients Infected or Colonized by Aspergillus fumigatus
Sarah Dellière, France
17:35
S18.6 Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19 Associated Pulmonary Aspergillosis (CAPA): A multicenter study
Brice Autier, France
Symposium 19 Pre clinical anti fungal studies
Chairs: Alexandra Brand, United Kingdom & Mihai Mares, Romania, FECMM
16:15
S19.1 Antifungal tolerance: spanning the genetic and phenotypic diversity of Candida albicans
Judy Berman, Israel
16:35
S19.2 Paradoxical growth
Carol Munro, United Kingdom
16:55
S19.3 BET bromodomain inhibition as a potential new antifungal therapeutic strategy
Jérôme Govin, France
17:15
S19.4 Use of animal infection models in preclinical antifungal development
David Andes, USA, FECMM
17:35
S19.5 Development of the Arabian killifish (Aphanius dispar) as a model host to study human fungal pathogens.
Mark Ramsdale, United Kingdom
Symposium 20 Improving outcomes for patients with invasive fungal infection in routine care in LMIC
Chairs: Rita Oladele, Nigeria, FECMM & Tom Harrison, United Kingdom
16:15
S20.1 From trials to routine care - strengthening pathways to effective implementation – lessons from cryptococcal meningitis and the UNITAID/CHAI programme for advanced HIV disease
Angela Loyse, United Kingdom
16:35
S20.2 CDC Mycology Branch programme to support diagnosis and treatment in LMIC
Tom Chiller, USA
16:55
S20.3 Improving outcomes for patients with sporotrichosis, chromoblastomycosis and mycetoma in South America
Flavio Queiros Telles, Brazil
17:15
S20.4 Mycology Expereince from a Cancer Hospital in Pakistan
Summiya Nizamuddin, Pakistan
17:30
S20.5 Laboratory diagnosis of invasive fungal infections in a low-resource setting: a five year retrospective study
Rebecca Peters, Nigeria
Symposium 21 Invasive fungal infections in special populations
Chairs: Volkan Özenci, Sweden & Silke Schelenz, United Kingdom, FECMM
16:15
S21.1 Neonatal candiasis
Tom Walsh, USA, FECMM
16:35
S21.2 ECMO and dialysis
Robert Krause, Austria, FECMM
16:55
S21.3 Obese patients
Roger Brüggemann, the Netherlands, FECMM
17:15
S21.4 NEOGLUCAN study: Serial (1–3) beta D Glucan levels in high risk neonates
Laura Ferreras-Antolin, United Kingdom
17:30
S21.5 Optimization of fluconazole therapy for the treatment of invasive candidiasis in preterm infants
Aline Engbers, the Netherlands
18:00
Sponsored Diagnostic Symposium 2
More information on https://www.timm2021.org/sponsored-symposia/
19:30
Congress dinner
Plenary session 3 Viral infection associated Pulmonary Aspergillosis / Going Viral Going Fungal
Chair: Tihana Bicanic, United Kingdom, FECMM
09:00
PS3.1 Influenza
Paul Verweij, the Netherlands, FECMM
09:30
PS3.2 COVID-19
Martin Hoenigl, Austria, FECMM
10:00
Coffee break
10:15
Quiz the expert sessions
10:15
Q07 MIC testing in the lab
Maiken Arendrup, Denmark
10:15
Q08 Mucormycosis how to manage
Livio Pagano, Italy, FECMM & Sharon Chen, Australia, FECMM
10:15
Q09 TDM
Andreas Groll, Germany, FECMM
10:15
Q10 Radiology
Joanne Cleverley, United Kingdom & Bruno Hochhegger, Brazil, FECMM
10:15
Q11 How to use new antifungals in kids
Fabianne Carlesse, Brazil
10:15
Q12 Mycological Diagnosis on the bedside: Where are we in 2021
John Perfect, USA & Toine Mercier, Belgium, FECMM
11:00
Poster session 2
12:00
Lunch
12:30
Sponsored Integrated Symposium 4
More information on www.timm2021.org/sponsored-symposia
14:15
Parallel Symposia 14-17
Symposium 14 Fungal respiratory infections in Cystic Fibrosis
Chairs: Jean-Philippe Bouchara, France & Michaela Lackner, Austria, FECMM
14:15
S14.1 Fungal infections in patients with cystic fibrosis
Michaela Lackner, Austria, FECMM
14:35
S14.2 Exophiala dermatitidis in cystic fibrosis
Jörg Steinmann, Germany, FECMM
14:55
S14.3 Immunotherapy
Darius Armstrong-James, United Kingdom, FECMM
Symposium 15 Cryptococosis: From bench to bedside
14:15
S15.1 Advancing prevention and treatment of HIV-associated cryptococcal meningitis
14:35
S15.2 AMBITION trial and beyond
Joe Jarvis, United Kingdom
14:55
S15.3 Titan cells in cryptococcosis
Liz Ballou, United Kingdom
15:15
S15.4 Modifications of the cell wall in cryptococcosis
Liliane Mukaremera, United Kingdom
Symposium 16 Azoles, Echinocandins and Polyenes strenghts and weaknesses
Chair: Frederic Lamoth, Switzerland, FECMM
14:15
S16.1 Azoles
Roger Brüggemann, the Netherlands, FECMM
14:35
S16.2 Echinocandins
Andrej Spec, USA, FECMM
14:55
S16.3 Polyenes and biofilms
Gordon Ramage, United Kingdom, FECMM
15:15
S16.4 Breakthrough infections - Definitions, Epidemiology and Outcomes
Jeff Jenks, USA
Symposium 17 Management of immunoallergic fungal diseases
14:15
S17.1 Antifungal treatment in kids with allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization : where do we stand?
Adilia Warris, United Kingdom, FECMM
14:35
S17.2
Peter Cook, United Kingdom
14:55
S17.3 Impact of environmental approaches for allergen avoidance and asthma control
Jean-Pierre Gangneux, France, FECMM
15:15
S18.4 Mycology laboratory diagnostic capabilities in different areas of the world
15:45
Coffee break
16:15
Parallel Symposia 18-21
Symposium 18 Diagnosis of invasive aspergillosis: What is new?
Chair: Lewis White, United Kingdom, FECMM
16:15
S18.1 Maldi
16:35
S18.2 POC
Juergen Prattes, Austria, FECMM
16:55
S18.3 PCR Diagnosis
Lewis White, United Kingdom, FECMM
Symposium 19 Pre clinical anti fungal studies
Chairs: Alexandra Brand, United Kingdom & Mihai Mares, Romania, FECMM
16:15
S19.1 Tracking antifungals in the cell
Judy Berman, Israel
16:35
S19.2 Paradoxical growth
Carol Munro, United Kingdom
16:55
S19.3 Screens for new compounds
17:15
S19.4 Animal models
David Andes, USA, FECMM
Symposium 20 Improving outcomes for patients with invasive fungal infection in routine care in LMIC
Chair: Rita Oladele, Nigeria, FECMM
16:15
S20.1 From trials to routine care - strengthening pathways to effective implementation – lessons from cryptococcal meningitis and the UNITAID/CHAI programme for advanced HIV disease
Angela Loyse, United Kingdom
16:35
S20.2 CDC Mycology Branch programme to support diagnosis and treatment in LMIC
Tom Chiller, USA
16:55
S20.3 Improving outcomes for patients with implantation mycoses in South America: Sporotrichosis, Chromoblastomycosis and Mycetoma
Flavio Queiros Telles, Brazil
Symposium 21 Invasive fungal infections in special populations
Chair: Volkan Özenci, Sweden
16:15
S21.1 Neonatal candiasis
Tom Walsh, USA, FECMM
16:35
S21.2 ECMO and dialysis
Robert Krause, Austria, FECMM
16:55
S21.3 Obese patients
Roger Brüggemann, the Netherlands, FECMM
18:00
Sponsored Diagnostic Symposium 2
More information on https://www.timm2021.org/sponsored-symposia/
19:30
Congress dinner